Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Vidal, Liat [VerfasserIn]   i
 Gafter-Gvili, Anat [VerfasserIn]   i
 Salles, Gilles [VerfasserIn]   i
 Dreyling, Martin H. [VerfasserIn]   i
 Ghielmini, Michele [VerfasserIn]   i
 Hsu Schmitz, Shu-Fang [VerfasserIn]   i
 Pettengell, Ruth [VerfasserIn]   i
 Witzens-Harig, Mathias [VerfasserIn]   i
 Shpilberg, Ofer [VerfasserIn]   i
Titel:Rituximab maintenance for the treatment of patients with follicular lymphoma
Titelzusatz:an updated systematic review and meta-analysis of randomized trials
Verf.angabe:Liat Vidal, Anat Gafter-Gvili, Gilles Salles, Martin H. Dreyling, Michele Ghielmini, Shu-Fang Hsu Schmitz, Ruth Pettengell, Mathias Witzens-Harig, Ofer Shpilberg
E-Jahr:2011
Jahr:October 21, 2011
Umfang:8 S.
Fussnoten:Gesehen am 08.12.2022
Titel Quelle:Enthalten in: National Cancer InstituteJournal of the National Cancer Institute
Ort Quelle:Oxford : Oxford Univ. Press, 1941
Jahr Quelle:2011
Band/Heft Quelle:103(2011), 23, Seite 1799-1806
ISSN Quelle:1460-2105
Abstract:In a previous systematic review and meta-analysis of five randomized controlled trials comparing rituximab maintenance with no maintenance (observation or rituximab at progression) for patients with follicular lymphoma, we reported that rituximab maintenance treatment improved the overall survival of patients. In this study, we did a similar search of the electronic databases updated through December 31, 2010, and included nine trials and 2586 follicular lymphoma patients. Hazard ratios (HRs) for time-to-event data were estimated and pooled using the inverse variance method. Risk ratios for dichotomous data were pooled using a fixed effect model. Patients treated with rituximab maintenance had improved overall survival (pooled HR of death = 0.76, 95% confidence interval [CI] = 0.62 to 0.92) compared with patients in the no maintenance group. Patients with refractory or relapsed (ie, previously treated) follicular lymphoma treated with rituximab maintenance had improved overall survival (pooled HR of death = 0.72, 95% CI = 0.57 to 0.91), whereas previously untreated patients had no survival benefit (pooled HR of death = 0.86, 95% CI = 0.60 to 1.25). The rate of infection-related adverse events was higher in the rituximab maintenance group (pooled risk ratio = 1.67, 95% CI = 1.40 to 2.00). These results further support the use of rituximab maintenance in the standard of care for refractory or relapsed follicular lymphoma.
DOI:doi:10.1093/jnci/djr418
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1093/jnci/djr418
 DOI: https://doi.org/10.1093/jnci/djr418
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1826601767
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68994435   QR-Code
zum Seitenanfang